 J Hamilton currently serves as vice president of Clinical Development at Arrowhead Pharmaceuticals , Inc. ( CA , USA) , where he is responsible for clinical strategy , clinical trial design , implementation and execution. In this role , he managed the ARC-520 , ARC-521 and ARC-AAT global programs. Previously , he was medical director and head of Corporate Development at Arrowhead. He led Arrowhead 's acquisition of the Novartis RNAi assets and led Arrowhead 's $ 670 million cardiovascular deal with Amgen ( CA , USA). He earned an MD and MBA at The Ohio State University ( USA) and is a licensed physician with board certification in emergency medicine. J Hamilton speaks to Hannah Makin , commissioning editor.